

## Human Octreotide (Synthetic) - Purified

**Catalog No.:** PA1195XC

**Quantity:** 25 mg

**Concentration:** 1.0 mg/ml

**Background:** Octreotide acetate is a longer acting synthetic octapeptide analog of naturally occurring somatostatin. It inhibits the secretion of gastro-entero-pancreatic peptide hormones and the release of growth hormone.

**Species:** Human

**Source:** Synthetic

**Format:** **State:** Sterile Filtered White lyophilized (freeze-dried) powder.

**Purity:** >98% Greater than 98.0% as determined by:

(a) Analysis by RP-HPLC.

(b) Anion-exchange FPLC.

(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.

**Buffer System:** Octreotide was lyophilized from a concentrated solution with no additives.

**Reconstitution:** It is recommended to reconstitute the lyophilized Octreotide in sterile 18MΩ-cm H<sub>2</sub>O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.

**Description:** Synthetic Human Octreotide is a single, non-glycosylated, polypeptide chain containing 8 amino acids, having a molecular formula of C<sub>49</sub>H<sub>66</sub>N<sub>10</sub>O<sub>10</sub>S<sub>2</sub>. Octreotide is purified by proprietary chromatographic techniques.

**AA Sequence:**

The sequence was determined to be H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol.

**Molecular weight:** 1019.26 Dalton

**Storage:** Lyophilized Octreotide although stable at room temperature, should be stored desiccated below 0°C. Reconstituted Octreotide is best stored refrigerated at 4°C. Please avoid freeze-thaw cycles.

**General Readings:**

1. The role of octreotide versus placebo in the prevention of post-ERCP pancreatitis. *Hepatology* 2007 Jan-Feb;54(73):250-3
2. Octreotide for esophageal variceal bleeding treated with endoscopic sclerotherapy: a randomized, placebo-controlled trial. *Hepatology* 2007 Jan-Feb;54(73):195-200
3. 68Ga-DOTA-Tyr<sup>3</sup>-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. *J Nucl Med* 2007 Apr;48(4):508-18
4. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. *Gastroenterology* 2007 Mar;132(3):1104-16

5. Administration of octreotide for management of postoperative high-flow chylothorax. Ann Vasc Surg 2007 Jan;21(1):90-2
6. Octreotide LAR for severe obscure-overt gastrointestinal haemorrhage in high-risk patients on anticoagulation therapy. Gut 2007 Mar;56(3):447